Umoja Biopharma has announced the closing of an oversubscribed $100m Series C financing round, which will enable the company to progress its in vivo chimeric antigen receptor (CAR)-T cell therapy ...

AbbVie has signed a wide-ranging collaboration with Umoja Biopharma in the area of ‘in situ’ or in vivo cell therapy, an emerging strategy that does away with the need to harvest, modify ...